Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Short-term Investments: 2017-2025

Historic Short-term Investments for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to $139.1 million.

  • Anaptysbio's Short-term Investments fell 41.68% to $139.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.1 million, marking a year-over-year decrease of 41.68%. This contributed to the annual value of $262.3 million for FY2024, which is 26.10% down from last year.
  • Per Anaptysbio's latest filing, its Short-term Investments stood at $139.1 million for Q3 2025, which was down 37.17% from $221.4 million recorded in Q2 2025.
  • Anaptysbio's 5-year Short-term Investments high stood at $394.3 million for Q2 2023, and its period low was $37.7 million during Q3 2021.
  • For the 3-year period, Anaptysbio's Short-term Investments averaged around $286.8 million, with its median value being $279.0 million (2024).
  • Per our database at Business Quant, Anaptysbio's Short-term Investments slumped by 70.79% in 2021 and then soared by 918.71% in 2022.
  • Over the past 5 years, Anaptysbio's Short-term Investments (Quarterly) stood at $52.4 million in 2021, then surged by 606.41% to $369.9 million in 2022, then decreased by 4.05% to $354.9 million in 2023, then declined by 26.10% to $262.3 million in 2024, then tumbled by 41.68% to $139.1 million in 2025.
  • Its Short-term Investments was $139.1 million in Q3 2025, compared to $221.4 million in Q2 2025 and $241.3 million in Q1 2025.